Selexis will develop research cell banks for a further three preclinical candidates in Teneobio’s oncology pipeline of multi-specific biologics. In June 2017, biotech firm Tenebio selected cell line development and biologics services firm Selexis, part of the JSR Life Sciences group, to develop research cell banks (RCBs) for multi-specific UniAb candidates for multiple myeloma. Tenebio has now extended the contract to use Selexis’ SUREtechnology Platform for three more of its multi-specific Human Heavy-Chain Antibodies candidates, known as UniAbs. “The resounding…